Optimizing foundational therapies in HF ‒ can we do better?

23 May 2022 (17:52 - 18:00)

Organised by:

Video

Sign in to view the resources

Slides

About the speaker

Professor Andrew Stewart Coats

Heart Research Institute, Sydney (Australia)

5 More presentations in this session

Presentation thumbnail

Welcome and introduction.

Professor S. Anker (Berlin, DE)

Presentation thumbnail

SGLT2 inhibition ‒ early, first-line therapy across the spectrum of HF.

Doctor D. Tomasoni (Brescia, IT)

Presentation thumbnail

SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion.

Professor G. Rosano (London, GB)

Presentation thumbnail

Interactive panel discussion.

Professor S. Anker (Berlin, DE) Professor A. Stewart Coats (Sydney, AU) Professor G. Rosano (London, GB) Doctor D. Tomasoni (Brescia, IT)

Presentation thumbnail

Conclusion.

Professor C. Lam (Singapore, SG)

Access the full session

Session thumbnail

SGLT2 inhibition across the spectrum of heart failure: maximizing patient benefits in clinical practice

The Event

Event poster

Heart Failure 2022

23 May 2022 17:52 CET

You may be interested in

Congress Session

Implementing use of heart failure treatments in clinical practice

24 May 2022

Congress Presentation

We should profile patients for tailored therapy implementation.

21 May 2022

Congress Presentation

Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction - a survey of the HFA and the CCP of the ESC

13 May 2024

Congress Presentation

Fast implementation strategies: what is the evidence?

27 August 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources